Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Abstract
Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma cell growth and resistance to conventional therapies. Although multiple myeloma remains incurable, novel targeted agents, used alone or in combination, have shown great promise to overcome conventional drug resistance and improve patient outcome. Recent oncogenomic studies have further advanced our understanding of the molecular pathogenesis of multiple myeloma, providing the framework for new prognostic classification and identifying new therapeutic targets.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activation of NF-KB, which is the outcome of the VLA4-VCAM1 molecule in multiple myeloma cells and mesenchymal stem cells, stimulates the transcription and release of the primary multiple myeloma cell growth molecule, IL-6.
“The activation of NF-KB, which is the outcome of the VLA4-VCAM1 molecule in MM cells and MSCs, stimulates the transcription and release of the primary MM cell growth molecule, IL-6 [102].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [102]
Cites
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246 · see citing works
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · see citing works
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · see citing works
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637 · see citing works
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis
Carrasco, D. R., Sukhdeo, K., Protopopova, M., Sinha, R., Enos, M., Carrasco, D. E., Zheng, M., Mani, M., Henderson, J., Pinkus, G. S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.015 · Cited by 414 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147 · see citing works
Self-citationHeterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875 · see citing works
Self-citationSanto, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616 · see citing works
Self-citationUmezu, T., Tadokoro, H., Azuma, K., Yoshizawa, S., Ohyashiki, K., & Ohyashiki, J. H. (2014) · Blood · doi:10.1182/blood-2014-05-576116 · Cited by 600 · see citing works
DNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428 · see citing works
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0200 · Cited by 309 · see citing works
Self-citationFitzgerald, D. P., Palmieri, D., Hua, E., Hargrave, E., Herring, J. M., Qian, Y., Vega-Valle, E., Weil, R. J., Stark, A. M., Vortmeyer, A. O., et al. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9193-z · Cited by 218 · see citing works
Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
van Andel, H., Kocemba, K. A., Spaargaren, M., & Pals, S. T. (2019) · Leukemia · doi:10.1038/s41375-019-0404-1 · Cited by 188 · see citing works
Garayoa, M., Garcia, J. L., Santamaria, C., Garcia-Gomez, A., Blanco, J. F., Pandiella, A., Hernández, J. M., Sanchez-Guijo, F. M., del Cañizo, M.-C., Gutiérrez, N. C., et al. (2009) · Leukemia · doi:10.1038/leu.2009.65 · Cited by 148 · see citing works
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159 · see citing works
Self-citationLiu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83 · see citing works
Self-citationAnti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., Sawada, N., Tsunoda, H., Shima, T., Miyawaki, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1216 · Cited by 80 · see citing works
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70 · see citing works
Self-citationDrug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65 · see citing works
Pang, J., Shi, Q., Liu, Z., He, J., Liu, H., Lin, P., Cui, J., & Yang, J. (2017) · Haematologica · doi:10.3324/haematol.2016.154062 · Cited by 57 · see citing works
Maiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48 · see citing works
Peng, Y., Li, F., Zhang, P., Wang, X., Shen, Y., Feng, Y., Jia, Y., Zhang, R., Hu, J., & He, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117503 · Cited by 42 · see citing works
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
Laubach, J. P., & Richardson, P. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3190 · Cited by 43 · see citing works
Self-citationCytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma
Akhtar, S., Ali, T. A., Faiyaz, A., Khan, O. S., Raza, S. S., Kulinski, M., Omri, H. E., Bhat, A. A., & Uddin, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145002 · Cited by 44 · see citing works
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40 · see citing works
Angiogenic activity of mesenchymal stem cells in multiple myeloma
Wang, X., Zhang, Z., & Yao, C. (2011) · Cancer Investigation · doi:10.3109/07357907.2010.496758 · Cited by 32 · see citing works
García-Sánchez, D., González-González, A., Alfonso-Fernández, A., Del Dujo-Gutiérrez, M., & Pérez-Campo, F. M. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i5.421 · Cited by 32 · see citing works
Arihara, Y., Takada, K., Kamihara, Y., Hayasaka, N., Nakamura, H., Murase, K., Ikeda, H., Iyama, S., Sato, T., Miyanishi, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19508 · Cited by 28 · see citing works
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works
“The activation of NF-KB, which is the outcome of the VLA4-VCAM1 molecule in MM cells and MSCs, stimulates the transcription and release of the primary MM cell growth molecule, IL-6 [102].”
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
Adamia, S., Bhatt, S., Wen, K., Chyra, Z., Fell, G. G., Tai, Y.-T., Pioso, M. S., Abiatari, I., Letai, A., Dorfman, D. M., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01475-z · Cited by 24 · see citing works
Self-citationAP-1 inhibitor induces ferroptosis via the PI3K/AKT pathway in multiple myeloma cells
Tang, S., Liu, J., Li, F., Yan, Y., Long, X., & Fu, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34397 · Cited by 13 · see citing works
- Authors
- Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C.
- Affiliations
- Harvard University (US)
- Corresponding author
- Anderson, Kenneth C.
- Venue
- Nature Reviews Cancer
- Published
- 2007-08
- Volume
- 7
- Issue
- 8
- Pages
- 585-598
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2010552629
- Cited by
- 932
- References
- 5
- Citations by year
- 2026: 21 · 2025: 21 · 2024: 28 · 2023: 43 · 2022: 51 · 2021: 55 · 2020: 51 · 2019: 38 · 2018: 44 · 2017: 45 · 2016: 53 · 2015: 60 · 2014: 69 · 2013: 63 · 2012: 74
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
- Keywords
- multiple myeloma, bone marrow microenvironment, pathogenesis, drug resistance, therapeutic target, plasma cell malignancy, chromosomal abnormalities, oncogenomics, prognostic stratification, targeted therapy
- MeSH terms
- Antineoplastic Agents, Bone Marrow, Humans, Multiple Myeloma, Drug Resistance, Neoplasm, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
